halothane has been researched along with Seizures in 42 studies
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
Excerpt | Relevance | Reference |
---|---|---|
"Toxic systemic reactions to bupivacaine usually involve a number of factors, including hypoxia and acidosis." | 7.68 | Severe hypoxia enhances central nervous system and cardiovascular toxicity of bupivacaine in lightly anesthetized pigs. ( Badgwell, JM; Bessire, A; Dryden, CF; Heavner, JE; Huemer, G; Sanghani, V, 1992) |
"We conducted a prospective study to examine the effect of pentobarbital administration on the development of seizures in dogs that had undergone cervical myelography with metrizamide while anesthetized with halothane." | 7.67 | Use of pentobarbital sodium to reduce seizures in dogs after cervical myelography with metrizamide. ( Gray, PR; Indrieri, RJ; Lowrie, CT, 1987) |
"infusion of 1." | 5.29 | Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat. ( Dexter, F; McFarlane, C; Todd, MM; Warner, DS, 1994) |
" Fatal cardiac arrhythmias occurred in, respectively, 3 of 11, 2 of 12, and 2 of 13 conscious sheep infused with bupivacaine, levobupivacaine, and ropivacaine; in 1 of 9 with prilocaine, electromechanical dissociation (followed by polymorphic ventricular tachycardia) caused death." | 3.74 | The effects of general anesthesia on the central nervous and cardiovascular system toxicity of local anesthetics. ( Copeland, SE; Gu, XQ; Ladd, LA; Mather, LE, 2008) |
" Induction doses of ketamine 1 hour after HD exposure resulted in periods of profound apnea, with continued respiratory distress for the next 2 hours." | 3.70 | Domestic swine model for the assessment of chemical warfare agent-anesthetic interactions: some effects of sulfur mustard. ( Conley, J; Hamilton, M; Hunter, K; Lundy, P; Sawyer, TW, 2000) |
"Toxic systemic reactions to bupivacaine usually involve a number of factors, including hypoxia and acidosis." | 3.68 | Severe hypoxia enhances central nervous system and cardiovascular toxicity of bupivacaine in lightly anesthetized pigs. ( Badgwell, JM; Bessire, A; Dryden, CF; Heavner, JE; Huemer, G; Sanghani, V, 1992) |
"We conducted a prospective study to examine the effect of pentobarbital administration on the development of seizures in dogs that had undergone cervical myelography with metrizamide while anesthetized with halothane." | 3.67 | Use of pentobarbital sodium to reduce seizures in dogs after cervical myelography with metrizamide. ( Gray, PR; Indrieri, RJ; Lowrie, CT, 1987) |
" Isoniazide and picrotoxin were used to increase motor activity and induce seizures associated with an increase in cerebellar cGMP content." | 3.66 | Halothane effect on cGMP and control of motor activity in mouse cerebellum. ( Alpert, M; Triner, L; Verosky, M; Vulliemoz, Y, 1981) |
" Local coupling of blood flow and metabolism was studied under different types of anesthesia (barbiturate, halothane), following experimental tumor implantation, and during penicillin seizures or spreading depression." | 3.66 | A double tracer autoradiographic technique for simultaneous measurement of cerebral blood flow and cerebral metabolism in rats. ( Hossmann, KA; Mies, G; Niebuhr, I, 1981) |
"The effect was most pronounced in seizure-prone animals, and subsequent to anaesthetic-induced behavioural immobility, these animals also showed a regional resistance to the depression of spontaneous slow potential shift oscillations." | 1.30 | Large slow potential shifts occur during halothane anaesthesia in gerbils. ( Laming, PR; Roughan, JV, 1998) |
"infusion of 1." | 1.29 | Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat. ( Dexter, F; McFarlane, C; Todd, MM; Warner, DS, 1994) |
"Bupivacaine was infused at a constant rate while the pigs' ECGs and EEGs were recorded." | 1.28 | Bupivacaine toxicity in young pigs is age-dependent and is affected by volatile anesthetics. ( Badgwell, JM; Heavner, JE; Kytta, J, 1990) |
"D-halothane and halothane were equipotent on both parameters." | 1.27 | Deuterated halothane--anesthetic potency, anticonvulsant activity, and effect on cerebellar cyclic guanosine 3',5'-monophosphate. ( Hamm, MW; Krishna, G; Triner, L; Verosky, M; Vulliemoz, Y, 1984) |
"The rise in seizure threshold still occurred when animals were pretreated with alpha-methyl-p-tyrosine (200 mg ." | 1.26 | Studies on the post-ictal rise in seizure threshold. ( Cowen, PJ; Green, AR; Nutt, DJ, 1981) |
"Tonic and clonic convulsions and death induced by electric shock were inhibited more by E." | 1.26 | [Pharmacological comparison between enflurane and halothane]. ( Inoki, R; Iwatsubo, K; Kitagawa, J; Shigenaga, Y, 1976) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 32 (76.19) | 18.7374 |
1990's | 7 (16.67) | 18.2507 |
2000's | 3 (7.14) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
MILLAR, TW | 1 |
Elsen, FP | 1 |
Liljelund, P | 1 |
Werner, DF | 1 |
Olsen, RW | 1 |
Homanics, GE | 1 |
Harrison, NL | 1 |
Copeland, SE | 1 |
Ladd, LA | 1 |
Gu, XQ | 1 |
Mather, LE | 1 |
Nutt, DJ | 1 |
Cowen, PJ | 1 |
Green, AR | 1 |
Triner, L | 2 |
Vulliemoz, Y | 2 |
Verosky, M | 2 |
Alpert, M | 1 |
Hamm, MW | 1 |
Krishna, G | 1 |
Mies, G | 1 |
Niebuhr, I | 1 |
Hossmann, KA | 1 |
Guedj, P | 1 |
Payraudeau-Schreiber, P | 1 |
McFarlane, C | 1 |
Warner, DS | 1 |
Dexter, F | 1 |
Todd, MM | 1 |
Roughan, JV | 1 |
Laming, PR | 1 |
Holzki, J | 1 |
Kretz, FJ | 1 |
Conley, J | 1 |
Hunter, K | 1 |
Lundy, P | 1 |
Hamilton, M | 1 |
Sawyer, TW | 1 |
Fisher, RS | 1 |
Prince, DA | 1 |
Huck, S | 1 |
Scarnati, E | 2 |
Forchetti, C | 2 |
Pacitti, C | 1 |
De Angelis, C | 2 |
Leonardis, G | 4 |
Wasterlain, CG | 1 |
Kryzhanovskiĭ, GN | 1 |
Makul'kin, RF | 1 |
Shandra, AA | 1 |
Harper, MH | 1 |
Winter, PM | 1 |
Johnson, BH | 1 |
Eger, EI | 2 |
Turnbull, MJ | 1 |
Watkins, JW | 1 |
Kitagawa, J | 1 |
Iwatsubo, K | 1 |
Shigenaga, Y | 1 |
Inoki, R | 1 |
Ogawa, T | 1 |
Shingu, K | 1 |
Shibata, M | 1 |
Osawa, M | 1 |
Mori, K | 1 |
Heavner, JE | 2 |
Dryden, CF | 1 |
Sanghani, V | 1 |
Huemer, G | 1 |
Bessire, A | 1 |
Badgwell, JM | 2 |
Kytta, J | 1 |
LaManna, JC | 1 |
McCracken, KA | 1 |
Patil, M | 1 |
Prohaska, OJ | 1 |
Lanier, WL | 1 |
Sharbrough, FW | 1 |
Michenfelder, JD | 1 |
Gray, PR | 1 |
Indrieri, RJ | 1 |
Lowrie, CT | 1 |
Komatsu, H | 1 |
Ogli, K | 1 |
De Jong, RH | 1 |
Robles, R | 1 |
Corbin, RW | 1 |
Joas, TA | 1 |
Stevens, WC | 1 |
Shim, CY | 1 |
Andersen, NB | 1 |
Myers, RR | 1 |
Stockard, JJ | 1 |
Fleming, NI | 1 |
France, CJ | 1 |
Bickford, RG | 1 |
Kilman, JW | 1 |
Williams, TE | 1 |
Kakos, GS | 1 |
Craenen, J | 1 |
Hosier, DM | 1 |
Bennett, DR | 1 |
Madsen, JA | 1 |
Jordan, WS | 1 |
Wiser, WC | 1 |
Sakabe, T | 1 |
Maekawa, T | 1 |
Ishikawa, T | 1 |
Takeshita, H | 1 |
Gattiker, R | 1 |
Lever, MJ | 1 |
Miller, KW | 1 |
Paton, WD | 1 |
Smith, EB | 1 |
Raventós, J | 1 |
Lemon, PG | 1 |
Splendiani, G | 2 |
Krenn, J | 1 |
Porges, P | 1 |
Steinbereithner, K | 1 |
Smith, PA | 1 |
Macdonald, TR | 1 |
Jones, CS | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Efficiency of Intravenous Lidocaine to Reduce Coughing and the Hemodynamic Changes Associated to Tracheal Extubation[NCT03731429] | Phase 4 | 144 participants (Anticipated) | Interventional | 2019-04-05 | Recruiting | ||
Prospective Cohort Study Evaluating Incidence and Correlation Between Pain and Emergence Delirium After Adenotonsillectomy in Preschool Children[NCT01096797] | Phase 4 | 150 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.27 |
Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.57 |
Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.09 |
Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.07 |
Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 6.3 |
Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -10.98 |
Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.05 |
Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.02 |
Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.04 |
Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.71 |
Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 1.23 |
Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.20 |
Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 0.95 |
Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -6.70 |
Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -7.12 |
Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -1.39 |
Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.67 |
Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.46 |
Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -3 |
Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | -0.15 |
Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) |
---|---|
Lidocaine | 2.46 |
Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
Intervention | Participants (Count of Participants) |
---|---|
Lidocaine | 87 |
Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
Intervention | units on a scale (Mean) | |
---|---|---|
1 year Change Work Activities | 1 year Change General health perception | |
Lidocaine | -1.37 | -0.28 |
Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
Intervention | units on a scale (Mean) | |
---|---|---|
6-Week Change Work activities | 6-Week Change General health perception | |
Lidocaine | 2.71 | -0.004 |
Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
---|---|---|---|---|
Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
42 other studies available for halothane and Seizures
Article | Year |
---|---|
Convulsions following halothane anaesthesia.
Topics: Anesthesia; Anesthetics; Halothane; Humans; Seizures | 1958 |
GABA(A)-R alpha1 subunit knockin mutation leads to abnormal EEG and anesthetic-induced seizure-like activity in mice.
Topics: Anesthetics; Animals; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography | 2006 |
The effects of general anesthesia on the central nervous and cardiovascular system toxicity of local anesthetics.
Topics: Acid-Base Equilibrium; Amides; Anesthetics, Inhalation; Anesthetics, Local; Animals; Arrhythmias, Ca | 2008 |
Studies on the post-ictal rise in seizure threshold.
Topics: Animals; Anticonvulsants; Bicuculline; Brain; Convulsants; Electroshock; GABA Antagonists; Halothane | 1981 |
Halothane effect on cGMP and control of motor activity in mouse cerebellum.
Topics: Animals; Cerebellum; Cyclic GMP; Halothane; Isoniazid; Male; Mice; Motor Activity; Picrotoxin; Seizu | 1981 |
Deuterated halothane--anesthetic potency, anticonvulsant activity, and effect on cerebellar cyclic guanosine 3',5'-monophosphate.
Topics: Animals; Cerebellum; Cyclic GMP; Deuterium; Drug Evaluation, Preclinical; Gas Chromatography-Mass Sp | 1984 |
A double tracer autoradiographic technique for simultaneous measurement of cerebral blood flow and cerebral metabolism in rats.
Topics: Animals; Antipyrine; Autoradiography; Brain; Brain Neoplasms; Cerebrovascular Circulation; Cortical | 1981 |
[An unusual cause of "post-critical" coma].
Topics: Adult; Brain; Coma; Dose-Response Relationship, Drug; Female; Halothane; Humans; Obstetric Labor Com | 1994 |
Glutamatergic antagonism: effects on lidocaine-induced seizures in the rat.
Topics: Animals; Electroencephalography; Excitatory Amino Acid Antagonists; Halothane; Lidocaine; Male; Pipe | 1994 |
Large slow potential shifts occur during halothane anaesthesia in gerbils.
Topics: Anesthesia; Animals; Behavior, Animal; Cerebral Cortex; Disease Susceptibility; Electrophysiology; G | 1998 |
Changing aspects of sevoflurane in paediatric anaesthesia: 1975-99.
Topics: Akathisia, Drug-Induced; Anesthesia, Inhalation; Anesthetics, Inhalation; Arrhythmias, Cardiac; Chil | 1999 |
Domestic swine model for the assessment of chemical warfare agent-anesthetic interactions: some effects of sulfur mustard.
Topics: Anesthesia, General; Anesthetics; Animals; Apnea; Chemical Warfare; Disease Models, Animal; Drug Eva | 2000 |
Spike-wave rhythms in cat cortex induced by parenteral penicillin. I. Electroencephalographic features.
Topics: Animals; Barbiturates; Cats; Cerebral Cortex; Disease Models, Animal; Electroencephalography; Haloth | 1977 |
The estimation of the survival rate of tetanus-intoxicated mice. A model for screening anti-tetanus drugs.
Topics: Animals; Chlorpromazine; Diazepam; Drug Evaluation, Preclinical; Halothane; Male; Mice; Phenobarbita | 1979 |
Modifications of penicillin-induced paroxystic hippocampal activity caused by ethrane and fluothane.
Topics: Animals; Anticonvulsants; Convulsants; Drug Interactions; Enflurane; Halothane; Male; Penicillins; R | 1979 |
Effects of epileptic seizures on brain ribosomes: mechanism and relationship to cerebral energy metabolism.
Topics: Age Factors; Animals; Brain; Energy Metabolism; Female; Halothane; Male; Methods; Mice; Nerve Tissue | 1977 |
[Principle of the determinant and formation of complexes of epileptic activity].
Topics: Animals; Bemegride; Cats; Cerebral Cortex; Electrophysiology; Ether; Halothane; Seizures; Strychnine | 1978 |
Naloxone does not antagonize general anesthesia in the rat.
Topics: Anesthesia, Inhalation; Animals; Dose-Response Relationship, Drug; Enkephalins; Halothane; Naloxone; | 1978 |
[Fluothane and experimental epilepsy. A neurophysiological study].
Topics: Animals; Anticonvulsants; Cerebral Cortex; Evoked Potentials; Female; Halothane; Male; Rats; Seizure | 1977 |
Determination of halothane-induced sleeping time in the rat: effect of prior administration of centrally active drugs.
Topics: Animals; Bemegride; Brain Chemistry; Circadian Rhythm; Drug Interactions; Female; Halothane; Injecti | 1976 |
[Pharmacological comparison between enflurane and halothane].
Topics: Animals; Dose-Response Relationship, Drug; Electroencephalography; Enflurane; Evoked Potentials; Fem | 1976 |
The divergent actions of volatile anaesthetics on background neuronal activity and reactive capability in the central nervous system in cats.
Topics: Amygdala; Animals; Brain; Cats; Electric Stimulation; Electroencephalography; Enflurane; Evoked Pote | 1992 |
Severe hypoxia enhances central nervous system and cardiovascular toxicity of bupivacaine in lightly anesthetized pigs.
Topics: Anesthesia, Inhalation; Animals; Arrhythmias, Cardiac; Blood Pressure; Bupivacaine; Electroencephalo | 1992 |
Bupivacaine toxicity in young pigs is age-dependent and is affected by volatile anesthetics.
Topics: Aging; Animals; Arrhythmias, Cardiac; Blood Pressure; Bupivacaine; Cardiac Output; Drug Interactions | 1990 |
Stimulus-activated changes in brain tissue temperature in the anesthetized rat.
Topics: Anesthesia; Animals; Body Temperature; Brain; Chloral Hydrate; Electric Stimulation; Electroencephal | 1989 |
Effects of atracurium, vecuronium or pancuronium pretreatment on lignocaine seizure thresholds in cats.
Topics: Anesthesia, Inhalation; Animals; Atracurium; Cats; Electroencephalography; Halothane; Lidocaine; Pan | 1988 |
Use of pentobarbital sodium to reduce seizures in dogs after cervical myelography with metrizamide.
Topics: Anesthesia, General; Animals; Body Weight; Dog Diseases; Dogs; Halothane; Metrizamide; Myelography; | 1987 |
Opisthotonus during exposure to isoflurane, enflurane, and halothane in mice.
Topics: Animals; Enflurane; Halothane; Isoflurane; Male; Mice; Mice, Inbred Strains; Seizures; Species Speci | 1987 |
Central actions of lidocaine--synaptic transmission.
Topics: Action Potentials; Anesthesia, Endotracheal; Animals; Blood Pressure; Cats; Halothane; Injections, I | 1969 |
Electroencephalographic seizure activity in dogs during anaesthesia.
Topics: Anesthetics; Animals; Carbon Dioxide; Chloroform; Cyclopropanes; Dogs; Electroencephalography; Ether | 1971 |
Minimal alveolar concentration (MAC) and dose-response curves in anesthesia.
Topics: Anesthesia, Inhalation; Anesthetics; Animals; Anura; Biological Assay; Brain; Chloroform; Cyclopropa | 1972 |
The use of on-line telephonic computer analysis of the E.E.G. in anaesthesia.
Topics: Anesthesia; Anesthesia, Inhalation; Animals; Cerebrovascular Circulation; Communication; Computers; | 1973 |
Surgical correction of the transposition complex in infancy.
Topics: Anesthesia, Inhalation; Child, Preschool; Edema; Extracorporeal Circulation; Female; Halothane; Hear | 1973 |
Ketamine anesthesia in brain-damaged epileptics. Electroencephalographic and clinical observations.
Topics: Adolescent; Adult; Anesthesia, Dental; Brain Damage, Chronic; Carbon Dioxide; Child; Child, Preschoo | 1973 |
The effects of lidocaine on canine cerebral metabolism and circulation related to the electroencephalogram.
Topics: Analysis of Variance; Animals; Blood Glucose; Blood Specimen Collection; Brain; Carbon Dioxide; Cere | 1974 |
[Anesthesia problems in clinical kidney transplantation].
Topics: Adult; Anesthesia, Endotracheal; Atropine; Coma; Female; Halothane; Humans; Kidney Transplantation; | 1967 |
Pressure reversal of anaesthesia.
Topics: Alcohols; Anesthesia, General; Anesthetics; Animals; Cell Membrane Permeability; Chemical Phenomena; | 1971 |
The impurities in Fluothane: their biological properties.
Topics: Adrenal Glands; Animals; Blood Chemical Analysis; Dogs; Halothane; Haplorhini; Heart; Hydrocarbons, | 1965 |
[Resuscitation of patients with convulsions].
Topics: Barbiturates; Eclampsia; Epilepsies, Partial; Epilepsy; Female; Halothane; Humans; Oxygen Inhalation | 1966 |
[Convulsions in infants. Problems of resuscitation].
Topics: Halothane; Humans; Infant; Infant, Newborn; Respiratory Tract Diseases; Resuscitation; Seizures | 1972 |
[Case of anesthesia convulsions under nitrous oxide-halothane anesthesia].
Topics: Anesthesia, General; Child; Electroencephalography; Halothane; Humans; Male; Nitrous Oxide; Seizures | 1967 |
Convulsions associated with halothane anaesthesia. Two case reports.
Topics: Anesthesia, Inhalation; Halothane; Humans; Infant; Male; Seizures | 1966 |